New Delhi, July 2 -- The Delhi High Court has directed the Drug Controller General of India (DCGI) to examine and address issues raised in a petition challenging the approval and sale of certain weight loss drug combinations in India.

The Court instructed the DCGI to consult medical experts, stakeholders, and drug manufacturers before arriving at any regulatory decision.

The bench of Justice Devendra Kumar Upadhyay and Justice Tushar Rao Gedela acknowledged the issues raised and stressed the need for initial regulatory scrutiny.

The petitioner has been permitted to submit an additional representation within two weeks, supplementing a previous one submitted in April.

The Court further directed the DCGI to provide a well-reasoned decisi...